Pathogenic mutations in the Leucine-rich repeat kinase 2 (LRRK2) are the predominant genetic cause of Parkinson's disease (PD). They increase its activity, resulting in augmented Rab10-Thr73 phosphorylation and conversely, LRRK2 inhibition decreases pRab10 levels. However, there is no assay to quantify pRab10 levels for drug target engagement or patient stratification. We developed an ultra-sensitive targeted mass spectrometry (MS)-based assay for determining Rab10-Thr73 phosphorylation stoichiometry in human samples. It uses synthetic stable isotope-labeled (SIL) analogues for both phosphorylated and nonphosphorylated tryptic peptides surrounding Rab10-Thr73 to directly derive the percentage of Rab10 phosphorylation from attomole amounts of the endogenous phosphopeptide. We test the reproducibility of our assay by determining Rab10-Thr73 phosphorylation stoichiometry in human neutrophils before and after LRRK2 inhibition. Compared to healthy controls, neutrophils of LRRK2 G2019S and VPS35 D620N carriers robustly display 1.4-fold and 3.7-fold increased pRab10 levels, respectively. Our generic MS-based assay further establishes the relevance of pRab10 as a prognostic PD marker and is a powerful tool for determining LRRK2 inhibitor efficacy and for stratifying PD patients for LRRK2 inhibitor treatment.
INTRODUCTION
Parkinson's disease (PD) is the second most common neurodegenerative disease, and no disease-modifying therapies exist to date 1, 2 .
Although most PD cases are idiopathic, mutations in several genes have been linked to familial forms of the disease 3 . Among those, mutations in the Leucine-rich repeat kinase 2 (LRRK2) comprise the predominant genetic cause of PD and account for 1% of sporadic and 4% of familial cases worldwide, and much higher in some populations 4 . At least six pathogenic missense mutations in LRRK2, including the most frequent G2019S substitution, have been identified 5 and several studies confirmed that these mutations increase its kinase activity [5] [6] [7] [8] . LRRK2-associated PD is clinically largely indistinguishable from idiopathic PD, suggesting that LRRK2 inhibition may be useful as disease-modifying therapy for a larger group of patients 4 . Clinical trials with selective LRRK2 kinase inhibitors are ongoing and have already passed phase 1.
We have recently identified a subset of Rab GTPases (Rab3A/B/C/D, Rab5A/B/C, Rab8A/B, Rab10, Rab12, Rab29, Rab35, and Rab43) as LRRK2 substrates 8, 9 . Among these, Rab10 appears to be a key physiological kinase substrate [8] [9] [10] [11] [12] [13] [14] .
LRRK2 directly phosphorylates Rab10 at Thr73 and all previously tested pathogenic forms of LRRK2 enhance this phosphorylation 8,9 . Intriguingly, the PD-associated D620N mutation of the retromer complex protein VPS35 also activates LRRK2 kinase activity, which in turn results in augmented Rab10 phosphorylation 15 . Thus, multiple PD-associated factors are interconnected and dysregulation of a common LRRK2-Rab signaling pathway may be an underlying cause of PD.
The LRRK2 autophosphorylation site Ser1292 has been widely used for assessing LRRK2 kinase activity [16] [17] [18] [19] . However, its phosphorylation levels appear to be extremely low and there is no sensitive phospho-specific antibody available to reliably detect and quantify phosphorylation at this site 6, 20, 21 . Instead, we recently developed several highaffinity antibodies for detecting pRab proteins in cells and in tissues 14 . Among those, a highly specific clone detects pThr73 levels in human peripheral blood cells of (mutant) LRRK2 G2019S and VPS35-D620N carriers 11, 15 . While pRab10 levels were markedly increased in VPS35 D620N carriers, no statistically significant differences in pRab10 levels were detected by immunoblotting analysis when comparing controls to LRRK2-G2019S carriers in peripheral blood mononuclear cells (PBMCs) and neutrophils 11, 15 . The reproducible quantification of immunoblots, particularly the detection of small (<2) foldchanges is challenging. In contrast, mass spectrometry-based quantification has become the gold standard and has several advantages over traditional biochemical methods, as it is more specific and more precise. Importantly, it allows simultaneous detection of both the phosphorylated peptide and the total protein pool and hence calculation of the absolute fraction of the phosphorylated protein, also known as phosphorylation stoichiometry or occupancy 22 .
There are several strategies differing in their accuracy, throughput, and applicability for measuring phosphorylation stoichiometry by MS [22] [23] [24] [25] [26] [27] . One way is to compare the intensities of modified and unmodified peptides by label-free proteomics 27 . However, due to potential differences in ionization efficiencies, the MS signals of individual peptides cannot be directly compared with each other. Stoichiometry determination based on heavy-to-light ratios of stable isotope-labeled (SIL) analogues of phosphorylated and non-phosphorylated proteolytic peptides and their endogenous counterparts can in principle overcome this problem and result in a much more sensitive and precise readout for monitoring kinase activity 22, 23 .
Alternatively, a SIL recombinant protein that is chemically or enzymatically phosphorylated can also be used as the spike-in standard 28, 29 . MS strategies determining stoichiometry that are combined with tailored targeted methods are especially suited for accurate quantification of low levels of a given phosphorylated analyte 30 . In particular, instruments with an Orbitrap as a mass analyzer can be operated in targeted scan modes such as high resolution selected ion monitoring (SIM) or parallel reaction monitoring (PRM). In both methods, precursor ions are isolated with a narrow m/z range by a quadrupole mass filter before introduction into the Orbitrap analyzer, thereby providing increased signal to noise ratio for the ion of interest and allowing attomole-level limits of detection 31, 32 . As no fragmentation is involved in SIM, quantification of selected ions relies on the high resolution in the Orbitrap mass analyzer. In contrast, in PRM, fragment ions are used for quantification of the peptide. While this approach is more specific, the overall sensitivity of PRM can be lower, as the signal of a given precursor ion is distributed across multiple fragments, although the signal to noise ratio can be higher 32 .
Here we describe an accurate and ultra-sensitive 
RESULTS

Rab10-pThr73 serves as a readout for LRRK2 activity in human peripheral blood neutrophils
To explore which Rab GTPases were expressed in human peripheral blood neutrophils and which of them could serve as a readout for LRRK2 activity in a quantitative MS-based assay, we first isolated neutrophils from whole blood using a negative selection approach. We assessed the recovery and the purity of the enriched cells by flow cytometry ( Supplementary Fig. 1 ). Proteomic analysis resulted in 5,488 quantified proteins, for which we estimated the copy numbers per cell using the proteomic ruler approach 33 Fig. 2 ).
To determine whether Rab10 is the only Rab family member that is phosphorylated by LRRK2 in neutrophils, we first treated freshly isolated cells with the selective LRRK2 inhibitor MLi-2 and confirmed the downregulation of Rab10-pThr73 by immunoblotting 11 (Fig. 1C ). In the same lysates, we enriched phosphorylated Rab proteins with the previously described pThr-specific Rab antibody and subjected the eluates to LC-MS/MS analysis 9 .
We detected 19 Rab GTPases in total, of which 7
were previously shown to be LRRK2 targets 9 ( Fig.   1D and Supplementary Fig. 3 To determine the maximum heavy-to-light ratio and the limit of quantification (LOQ) of our method, we mixed 25 fmol of the light pRab10 peptide with variable amounts of its heavy counterpart (10 amol to 50 fmol) in 50 ng of HeLa digest. The correlation for mxSIM indicates an excellent reproducibility of quantification also in the multiplexed case (R 2 = 0.997) ( Fig. 1G ). Due to the differential filling strategy, we accurately quantified heavy-to-light ratios of Rab10 Fig. 5A-B ). We then derived the Rab10-Thr73 phosphorylation stoichiometry as described above, which turned out to be 66.62 ± 1.54%. Subsequently, we used the same measurement but calculated the occupancy with the peptide-centric approach, yielding 67.17 ± 1.10%.
As both approaches gave nearly equal results, we decided to use the simpler peptide centric approach for all further calculations ( Fig. 2B ). directed against the epitope tag (50.86 ± 0.5% vs 67.17 ± 1.1%). A potential explanation for this discrepancy could be that the anti-Rab10 antibody preferentially recognizes the non-phosphorylated fraction of the total protein pool ( Fig. 2B and C).
Detection
To address this issue with a different approach that does not rely on antibodies, we separated the cell 2C ). We therefore decided to combine gelseparation, SIL peptide spike-in and the peptidecentric calculation approach. With these tools in hand, we extended our in-gel digestion workflow to endogenous Rab10-pThr73 occupancy determination. We found that 58.03 ± 0.94% of the protein was phosphorylated in LRRK2-Y1699Ctransfected cells, whereas the treatment with MLi-2 almost completely abolished the phosphooccupancy (0.89 ± 0.03%) ( Fig. 2D ).
To further benchmark our assay, we incubated recombinant Rab10 (1-175 aa) with LRRK2 and stopped the phosphorylation reaction by adding the LRRK2 inhibitor HG-10-102-01 at defined time intervals. Next, we determined the percentages of the phosphorylated Rab10 proteins by intact mass spectrometry and compared these values to the occupancies obtained using our mxSIM method ( Supplementary Fig. 6 ). This experiment revealed an excellent correlation between these methods in two independent experiments with R 2 of 0.984 and 0.994 ( Fig. 2E) . Similarly, to specifically test the SIL peptide spike-in part of the approach, we Table 2 ).
Finally, we performed a MLi-2 dose-response experiment (1-100 nM) using neutrophils from two donors and determined their occupancy based-IC50 values. These were very similar in both donors (2.44 and 3 nM), further demonstrating the high reproducibility of our method even in vivo ( Fig.3G and H). Total Rab10 levels did not differ between treated and untreated, and healthy controls and heterozygous G2019S mutation carriers (Fig. 4A ).
The median occupancy of Rab10-pThr73 were 3.06 ± 0.14% in healthy controls whereas they increased by about 1.4-fold to 4.29 ± 0.59% in G2019S carriers. Although our data shows that Rab10-pThr73 is increased in G2019S carriers, the observed differences did not reach statistical significance due to the large intergroup variability and the small cohort size (Fig. 4C ). In MLi-2 treated samples, occupancy decreased 5-fold on average for both groups (Fig. 4B ).
Our previous work demonstrated that VPS35 controls LRRK2 activity and that the D620N substitution resulted in increased LRRK2 activity as assessed by monitoring phospho-Rabs levels 15 . respectively, and decreased 6.9-fold on average in MLi-2 treated cells ( Fig. 4E ). While the 1.6-fold increase of Rab10-pThr73 in idiopathic PD was not statistically significant, the absolute Rab10-pThr73 occupancy in heterozygous VPS35 D620N patients was significantly higher compared to controls and idiopathic cases (Fig. 4F ). Together, these experiments demonstrate that our assay can reveal patients with higher LRRK2 kinase activity and suggest that it can be applied to stratify patients. We find that the levels of Rab10-Thr73 phosphorylation are stable but very low in human cells (<5%). This is also true for LRRK2-G2019S 
MATERIAL AND METHODS
Reagents
MLi-2 (cat# 5756) was purchased from Tocris Bioscience. DIFP, HA-agarose and trypsin were from Sigma and LysC was from Wako.
Microcystin-LR was from Enzo Life Sciences.
Complete protease and phosphatase inhibitor tablets were from Roche. SIL peptides in absolute quantities (AQUA) were purchased from Sigma-Aldrich. Clean peptides were fractionated using the high-pH reversed-phase `Spider fractionator` into 24
fractions as described previously to generate deep proteomes 37 . For the LOD experiment (Fig. 1 Supplementary Fig 1. Flow cytometry analysis determining the purity of the isolation method and viability of isolated neutrophils. Plots and population gating shown is for the donor used in the experiment in Figure 1C -D. Cell debris, non-leukocytes, and dead cells were excluded from the analysis based on scatter signals and DAPI. Purity was assessed by staining with CD14-PerCP (monocytes and macrophages), CD15-PE (granulocytes, monocytes, neutrophils and eosinophils), CD16-APC (neutrophils, macrophages and eosinophils), and CD193-FITC (eosinophils). The population which is CD15+ and CD16+ but CD14-and CD193-represents the neutrophils. The isolated cells had a viability >96% and a purity>98%. RAB11B  RAB7A  RAB1B  RAB27A  RAB10  RAB5B  RAB2A  RAB31  RAB14  RAB21  RAB8B  RAB3D  RAB5C  RAB6A  RAB24  RAB32  RAB1A  RAB18  RAB43  RAB35  RAB33B  RAB8A  RAB4B  RAB44  RAB5A  RAB37  RAB27B  RAB9A  RAB22A  RAB3A  RAB13  RAB19  RAB6A  RAB12  RAB28  RAB20  RAB23  RAB2B  10 LRRK1 and LRRK2 proteins. Supplementary Fig. 3 . LRRK2 dependent Rab GTPase phosphorylations in human neutrophils. Volcano plots of the pRab immunoprecipitations (untreated:right and MLi-2-treated:left). All Rab proteins identified were highligted in blue and LRRK2 substrates were also labeled. 
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